MedTrace Logo

TESTO-TRIAL: Use of Testosterone in Critically Ill Patients

NCT06592144 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2024-12-18

No results posted yet for this study

Summary

The objective of this study is to evaluate whether the use of the anabolic agent testosterone cypionate in critically ill patients, compared to placebo, increases the number of ventilator-free days

Conditions

  • Weaning Failure
  • Muscle Weakness
  • Mechanical Ventilation Complication
  • ICU Acquired Weakness
  • Mobility Limitation

Interventions

DRUG

Testosterone cypionate (200mg/3ml)

It will be administered intramuscularly every 5 days, totaling 3 doses.

OTHER

Sesame oil (3ml)

It will be administered intramuscularly every 5 days, totaling 3 doses.

Sponsors & Collaborators

  • Leticia Maria Defendi Barboza Marson

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-09
Primary Completion
2026-08-02
Completion
2026-11-02

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06592144 on ClinicalTrials.gov